This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Today, AbbVie charges approximately $77,000 for a year’s supply of Humira—470% more than when the drug was launched in 2003. Today, Imbruvica is priced at $181,529 per year for a patient taking three pills per day, compared to $99,776 per year at launch. net revenue from Humira. The last of these patents is set to expire in 2037.
Struggling with burnout while maintaining high-quality healthcare services that patients love? Tune in to our latest podcast as Lee Aase, founder of HELPCare, LLC, shares how he transitioned from his pioneering social media work at Mayo Clinic to lead an innovative membership-based direct-to-patient healthcare business. It was scary.
She offers tips and insights on how to write a winning medical sales resume that will help you stand out from the competition and land your dream job. I have seen over time the evolution of relationship management and holistic patient care since then. It’s about partnering to ensure the best patient outcomes. They’re online.
This article will explore how life sciences marketers can increase their competitive advantage by applying the discipline’s basic principles to their own strategies. In terms of branding, this judo principle lies at the nexus of three interrelated concepts: market research, competitive analysis, and brand positioning.
AstraZeneca ’s cholesterol drug Crestor (rosuvastatin) was approved in 2003 in the US but only approved in Germany in 2008. This was a landmark event as Vazkepa was the first FDA-approved drug for use in combination with statin therapies for hypertriglyceridemic patients. Cardiovascular disease landscape.
Will posting rates online actually help patients shop around for the best, most affordable care? He is responsible for positioning the company to provide value to its members, partners, and community through innovative and affordable patient care. The regulation required concrete companies to disclose negotiated prices.
Will posting rates online actually help patients shop around for the best, most affordable care? He is responsible for positioning the company to provide value to its members, partners, and community through innovative and affordable patient care. The regulation required concrete companies to disclose negotiated prices.
In the medical device business, the capacity for innovation is commonly regarded as a key competence and a powerful response mechanism for companies operating in our complex and highly competitive environment. The purpose of this post is to help MedTech professionals to better understand the different types of innovation.
It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.
16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine.
Each of these topics would represent sweeping changes on their own, and together, the IRA represents arguably the largest change to prescription drug financing in the United States since the Medicare Modernization Act of 2003, which started the Part D program. Maximum patient Part D out-of-pocket set at $2,000.
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. Switching patients from brand to biosimilar, as well as between biosimilars, was also highlighted in the survey. pharmaceutical industry. pharmaceutical industry.
Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. The waiver allows patients to be seen across geographic lines and in any setting. As of Aug.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content